pharmaphorum
JULY 29, 2021
Advanz hiked the price of a pack of liothyronine tablets – used to treat thyroid hormone deficiency – from £20 in 2009 to £248 in 2017, taking advantage of a lack of competition for the drug even though it was out of patent. The post UK fines Advanz £100m for raising thyroid drug price tenfold appeared first on.
pharmaphorum
AUGUST 20, 2020
illegally paid Medicare co-payment costs through purportedly independent charities while at the same time jacking up the price of Copaxone, which had no generic rival at the time. The US government alleges that the payments occurred from 2007 until the end of 2015, to charities called The Assistance Fund (TAF) and Chronic Disease Fund (CDF).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
SEPTEMBER 24, 2020
Gilead has paid $97 million to resolve claims by US authorities that it acted illegally by using a charitable foundation as a conduit to fund co-payments of thousands of Medicare patients taking its pulmonary arterial hypertension drug, Letairis.
Putting Patients First Blog
SEPTEMBER 7, 2023
The Duchenne Registry began in 2007, when a group of thought leaders in the Duchenne muscular dystrophy community began discussing the need for a new kind of resource that would connect and serve the needs of the entire community. The average age at loss of ambulation for registrants who never used corticosteroids was 10.5
European Pharmaceutical Review
SEPTEMBER 14, 2023
Market uncertainty Rising operational costs, stiffening competition, ongoing patent expirations, evolving environmental and social governance requirements and increasing pressure on drug prices mean the industry will have to navigate thoughtfully to be successful amid this complicated mix of financial and strategic risks.
pharmaphorum
JULY 15, 2022
Teva has asked the Supreme Court to look at a judgment in a $235 million patent dispute with GSK that it claims could undermine the ability of generic drugmakers to bring new products to market, and thereby help reduce drug prices. The substance patent expired in 2007.
pharmaphorum
APRIL 13, 2022
The organisation noted that the average net cost of these insulin products is 20% lower than in 2007. Unfortunately, the current drug pricing bill fails to take a holistic approach to addressing a system that drives affordability challenges for patients.
Expert insights. Personalized for you.
98 
Let's personalize your content